Review Article
DOI: https://doi.org/10.70749/ijbr.v3i6.1466

INDUS JOURNAL OF BIOSCIENCE RESEARCH
https://induspublishers.com/IJBR
ISSN: 2960-2793/ 2960-2807

Crossref

OPEN ACCESS

Nanoparticles in Infectious Disease Control: Microbial Synthesis, Antimicrobial Mechanisms, and Therapeutic Innovations

Anam Abbas[1], Saleha Ilyas[2], Hina Salahuddin[3], Muhammad Talha Talib[4], Muhammad Asif[5], Samavia Mustafa[1], Ayesha Bint-E-Bilal[7], Maliha Ghaffar[1]

[1]Department of Biology, University of Okara, Pakistan
[2]Veterinary Diagnostics Lab, Lahore, Pakistan
[3]Department of Zoology, University of Okara, Pakistan
[4]Department of Clinical Sciences, University of Veterinary and Animal Science, Lahore (Sub-Campus Jhang), Pakistan
[5]Shifa College of Medical Technology, Shifa Tameer-e-Millat University Islamabad, Pakistan
[7]University of Veterinary and Animal Science, Lahore, Pakistan

ARTICLE INFO

Keywords: Nanoparticles, Infectious Diseases, Antimicrobial Activity, Microbial Synthesis, Green Synthesis, Multidrug Resistance, Drug Delivery, Microbiology

Correspondence to: Maliha Ghaffar, Department of Biology, University of Okara, Pakistan
Email: maliha.ghaffar@uo.edu.pk

Declaration
Authors' Contribution: All authors equally contributed to the study and approved the final manuscript.

Conflict of Interest: No conflict of interest.

Funding: No funding received by the authors.

Article History
Received: 29-03-2025 Revised: 13-05-2025
Accepted: 29-05-2025 Published: 11-06-2025

ABSTRACT

The escalating threat of multidrug-resistant (MDR) pathogens has underscored the urgent need for innovative strategies to combat infectious diseases. Nanoparticles (NPs) have emerged as a versatile platform due to their unique physicochemical properties and potent antimicrobial capabilities. This review provides an in-depth analysis of NPs in infectious disease management, emphasizing their antimicrobial mechanisms, microbial synthesis, and therapeutic applications. Metal-based NPs, such as silver (AgNPs), zinc oxide (ZnO NPs), and copper oxide (CuO NPs), disrupt microbial cell membranes, generate reactive oxygen species (ROS), and inhibit biofilms, making them effective against bacteria, viruses, fungi, and parasites. Green synthesis using bacteria, fungi, and algae offers a sustainable, biocompatible approach to NP production, enhancing their suitability for medical applications. NPs improve drug delivery, overcome MDR, and support advanced therapies, including wound healing, antiviral treatments, vaccine development, and immunotherapy. This review also explores NP interactions with the microbiome, diagnostic applications, and specific bacterial infectious diseases—such as tuberculosis, pneumonia, urinary tract infections, skin infections, *Helicobacter pylori* infections, and *Clostridium difficile* infections along with their NP-based treatments. Challenges like toxicity, scalability, regulatory hurdles, and potential NP resistance are discussed, alongside future directions involving CRISPR and AI-driven NP design.

INTRODUCTION

The continued presence of infectious diseases caused by multidrug-resistant (MDR) pathogens, including methicillin-resistant *Staphylococcus aureus* (MRSA), carbapenem-resistant *Enterobacteriaceae*, and extensively drug-resistant *Mycobacterium tuberculosis*, poses a critical threat to global health [1]. Due to the slow pace of new antimicrobial compound development and the diminished effectiveness of traditional antibiotics, there is an emergent need for novel therapeutic methods [2]. Nanotechnology, and more particularly the application of nanoparticles (NPs), offers a hopeful remedy because of their special physicochemical characteristics, such as high surface area-to-volume ratio, tunable surface chemistry, and increased reactivity [3]. Such features allow NPs to improve drug delivery, break resistance barriers, and fight infections in a variety of mechanisms. Environmentally friendly fabrication of NPs through microbe-based synthesis like algae, fungi, and bacteria represents a biocompatible and sustainable approach to manufacturing antimicrobial agents with the added benefit of promoting environmental as well as global health objectives [4]. All the aspects of antimicrobial mechanisms, microbial synthesis, therapeutic uses, interactions with the microbiome, diagnostic applications, and certain bacterial infectious diseases with NP-based treatments are explicitly detailed in this review of the role of NPs in controlling infectious diseases. Problems and suggestions for future developments are also discussed.

Antimicrobial Mechanisms of Nanoparticles

Nanoparticles, which range in size from 1 to 100 nanometers, have extraordinary antimicrobial activity

against a wide range of pathogens such as bacteria, viruses, fungi, and parasites. Due to their interaction with microbial cells facilitated by the size and the high surface area, the NPs possess more than one mechanism of action, a feature distinguishing them from conventional antibiotics.

Figure 1

Antimicrobial Activity of Nanoparticles Membrane Disruption and Cellular Penetration



One of the chief mechanisms through which NPs execute their antimicrobial activities is by disturbing microorganism membranes. Metal nanoparticles (NPs) including silver (AgNPs), zinc oxide (ZnO NPs), and copper oxide (CuO NPs) are involved in interacting with bacterial cell membrane lipid bilayers, leading to structural impairment and leakage of cellular contents [5]. For example, it has been demonstrated that AgNPs produce reactive oxygen species (ROS), which cause damage to *Escherichia coli* cell walls and lead to cell death [6]. Similarly, NPs can enter microbial cells and disrupt critical intracellular processes like DNA replication, enzyme activity, and protein synthesis. CuO NPs suppress metabolic processes and curb bacterial growth by combining with thiol groups of key bacterial enzymes [7]. It has also been shown that gold nanoparticles (AuNPs) interfere with the ribosomal activity in *S. aureus*, further reducing protein synthesis and cell viability [8].

Oxidative Stress and Biofilm Inhibition

Since MDR pathogens such as *Klebsiella pneumoniae* generate ROS, which cause oxidative stress and damage to microbial DNA, proteins, and lipids, NPs are effective against these pathogens [9]. This oxidative stress overcomes the antioxidant defenses in the microbes, leading to irreversible cellular damage [10]. NPs are also very effective in halting biofilm formation, which is the most daunting problem in treating chronic infections. NPs like AgNPs and AuNPs interfere with quorum sensing and extracellular matrix production, inhibiting the development of biofilms by *Pseudomonas aeruginosa*, which are well known for being resistant to standard antibiotics [11]. By releasing metal ions like Ag^{+} and Cu^{2+}, NPs enhance their antimicrobial activity and additionally interfere with microbial homeostasis [12]. NPs, such as ZnO NPs (used topically) and AgNPs (active against *P. aeruginosa, S. aureus*, and viruses such as HIV and SARS-CoV-2), are dynamic agents against infectious diseases due to these dual mechanisms [13].

Microbial Synthesis of Nanoparticles

Green synthesis, involving microbes to produce NPs with antimicrobial properties, is an ecofriendly, cost-effective, and biocompatible alternative to chemical methods.

Figure 2

Methods for Nanoparticles Synthesis



Bacterial Synthesis

Pseudomonas stutzeri, Bacillus subtilis, and *Lactobacillus* species are some of the bacteria that naturally synthesize AgNPs and AuNPs. Utilizing enzymes such as nitrate reductase to reduce metal ions to NPs, these bacteria generate stable, antimicrobial particles [14]. For instance, *Shewanella oneidensis* has been utilized in the production of palladium nanoparticles (NPs), which have both catalytic and antimicrobial activity [15]. The process of bacterial synthesis is very effective in minimizing energy expenses and its negative impacts on the environment since it employs a large amount of microbial resources and takes place in a mild environment.

Fungal and Algal Synthesis

Fungi like *Aspergillus niger, Fusarium oxysporum*, and *Trichoderma reesei* offer scalability in NP production due to their high biomass and ability to secrete proteins and secondary metabolites that encourage extracellular NP synthesis [16]. AgNPs, AuNPs, and ZnO NPs are among the stable and biocompatible NPs produced by these fungi [17]. In a similar vein, photosynthetic machinery in algae with potent antimicrobial activity, such as Chlorella vulgaris and Spirulina platensis, produces AuNPs and AgNPs [18]. Algal synthesis is particularly advantageous for environmental sustainability because it avoids hazardous chemicals and uses renewable resources [19]. Biocompatibility, sustainability, adaptability, and cost-effectiveness are some of the benefits of microbial synthesis; however, issues such as regulating NP size and shape still exist, and synthetic biology may be able to help [20].

Therapeutic Applications of Nanoparticles

NPs have revolutionized the treatment of infectious diseases by enhancing drug delivery, preventing resistance, and creating new therapeutic and diagnostic opportunities. Because of their versatility, they are crucial to next-generation antimicrobial strategies.

Figure 3
Therapeutic Applications of Nanoparticles Enhanced Drug Delivery



NPs overcome the drawbacks of traditional antibiotics by dramatically increasing drug bioavailability and lowering systemic toxicity. Vancomycin is better delivered to infection sites by liposomal NPs, which guarantees greater local concentrations and increased effectiveness [21]. By delivering antitubercular medications straight to M. tuberculosis-infected macrophages, poly (lactic-co-glycolic acid) (PLGA) NPs maximize intracellular drug levels while reducing adverse effects [22]. Therapeutic results are improved by the controlled release of antimicrobials provided by mesoporous silica nanoparticles [23].

Combating Multidrug Resistance

By avoiding resistance mechanisms, NPs make current antibiotics effective again. AgNPs have synergistic effects against MDR strains and improve bacterial killing when paired with antibiotics such as ciprofloxacin or amoxicillin [24]. When treating chronic infections, chitosan nanoparticles (NPs) enhance the penetration of antibiotics through *Pseudomonas aeruginosa* biofilms, a significant obstacle [25]. By breaking down bacterial membranes, nitric oxide-releasing nanoparticles offer a fresh strategy for getting past resistance [26].

Antiviral and Antifungal Therapies

NPs have the potential to treat fungal and viral infections. AgNPs are effective against HIV and SARS-CoV-2 because they bind to glycoproteins and prevent viral entry [27]. Polymeric NPs loaded with amphotericin B have strong antifungal activity against Candida albicans while lowering toxicity [28]. A broad-spectrum antiviral approach is provided by graphene-based NPs, which break viral envelopes [29].

Wound Healing and Infection Control

In order to prevent and treat infections, NPs are incorporated into sophisticated dressings. By lowering the bacterial load and encouraging tissue regeneration, AgNP-impregnated hydrogels hasten healing [30]. Under UV light, ZnO NPs fight wound infections and offer extra antimicrobial defense [31].

Diagnostic Innovations

Rapid and sensitive diagnostics are made possible by NPs. AuNPs provide affordable diagnostics by detecting viral antigens or bacterial DNA in colorimetric assays [32]. Early detection of pathogens such as *M. tuberculosis* is made possible by the enhancement of imaging and biosensing by quantum dots and magnetic nanoparticles [33].

Specific Bacterial Infectious Diseases and NP-Based Treatments

By improving drug delivery, overcoming resistance, and specifically targeting bacterial cells, NPs provide targeted solutions for bacterial infectious diseases, especially those brought on by MDR pathogens. For clarity, complete reference details are integrated into the following subsections, which describe particular diseases and their NP-based treatments.

Tuberculosis (*Mycobacterium Tuberculosis*)

Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), continues to be a major cause of death globally, and MDR-TB presents particular difficulties because of its resistance to first-line medications. By enhancing drug delivery and focusing on the pathogen, NPs improve TB treatment. According to Dube et al. (2014, Nanomedicine: Nanotechnology, Biology and Medicine, 10(4), 831–838 [34]), isoniazid-loaded poly (lactic-co-glycolic acid) (PLGA) NPs deliver the medication to infected macrophages, achieving higher intracellular concentrations and lowering toxicity. According to Singh et al. (2016, Nanotechnology, 27(8), 085107 [35]), silver nanoparticles (AgNPs) provide a complementary strategy by breaking down M. tuberculosis cell walls and preventing the formation of biofilms. According to Chuan et al. (2013, International Journal of Pharmaceutics, 448(1), 135–141 [36]), rifampicin-encapsulated liposomes enhance lung tissue delivery and improve results in animal models. According to the World Health Organization's 2021 Global Tuberculosis Report [32], these tactics successfully combat MDR-TB.

Pneumonia (*Streptococcus Pneumoniae*, *Klebsiella Pneumoniae*)

Streptococcus pneumoniae and Klebsiella pneumoniae are the two main causes of bacterial pneumonia, which poses a serious health risk, especially when MDR strains are present. According to Jiang et al. (2018, Frontiers in Microbiology, 9, 2709 [37]), zinc oxide nanoparticles (ZnO NPs) break down the cell membranes of S. pneumoniae and produce reactive oxygen species (ROS), which lowers the bacterial load. According to Brown et al. (2012, Applied and Environmental Microbiology, 78(8), 2768–2774 [38]), AgNPs and azithromycin overcome resistance in MDR K. pneumoniae. Ahmadi et al. (2020, Journal of Medical Microbiology, 69(6), 831–837 [39]) demonstrated that copper oxide nanoparticles (CuO NPs) inhibit K. pneumoniae biofilms, thereby treating ventilator-associated pneumonia. These methods enhance pneumonia outcomes. Thorax, 68(11), 1057–1065 [33]; Torres et al., 2013).

Urinary Tract Infections (*Escherichia Coli*, *Proteus Mirabilis*)

Because of biofilms, urinary tract infections (UTIs), which are mostly brought on by Escherichia coli and Proteus mirabilis, frequently recur. According to Shariati et al. (2020, International Journal of Biological Macromolecules,

165(Pt A), 1392–1402 [40]), chitosan NPs loaded with ciprofloxacin break through E. coli biofilms and decrease recurrence. According to Qais et al. (2019, Nanomaterials, 9(3), 441 [41]), AgNPs prevent catheter-associated UTIs by interfering with P. mirabilis urease activity. According to Wang et al. (2021, Journal of Nanobiotechnology, 19(1), 112 [42]), selenium nanoparticles prevent E. coli adhesion. These tactics deal with UTI resistance (Flores-Mireles et al., 2015, Nature Reviews Microbiology, 13(5), 269–284 [34]).

Skin and Soft Tissue Infections (*Staphylococcus Aureus*)

Biofilms make methicillin-resistant *Staphylococcus aureus* (MRSA) skin infections difficult to treat. According to Rai et al. (2009, Biotechnology Advances, 27(1), 76–83 [43]), AgNP-impregnated dressings lower the MRSA load and encourage healing. According to Gu et al. (2003, Nano Letters, 3(9), 1261–1263 [44]), gold nanoparticles (AuNPs) combined with vancomycin break through biofilms and increase efficacy. According to Jesline et al. (2015, Applied Nanoscience, 5(2), 157–162 [45]), titanium dioxide NPs (TiO_2 NPs) produce ROS to eradicate *S. aureus*. Wound outcomes are improved by these interventions (Tong et al., 2015, Clinical Microbiology Reviews, 28(3), 603–661 [35]).

Helicobacter pylori Infections

Peptic ulcers and gastric cancer are caused by Helicobacter pylori, and treatment is made more difficult by antibiotic resistance. According to Angsantikul et al. (2018, Advanced Therapeutics, 1(2), 1800016 [49]), biomimetic nanoparticles (AGS-NPs) coated with gastric epithelial cell membranes deliver clarithromycin to H. pylori, reducing the bacterial burden by 3.08 orders of magnitude in mouse models. This focused method provides a precision approach to treating resistant *H. pylori* infections by reducing off-target effects.

Clostridium Difficile Infections

Antibiotic-associated diarrhea is caused by *Clostridium difficile*, and resistant spores can be problematic. According to Lee et al. (2019, Frontiers in Pharmacology, 10, 1153 [50]), vancomycin-loaded iron oxide nanoparticles (van-IONPs) bind C. difficile spores, postponing germination and lowering mortality in murine models. Van-IONPs provide a novel treatment for recurrent *C. difficile* infections by blocking spore-mucosal interactions.

Microbiological Integration and Microbiome Interactions

Beyond synthesis, NPs and microbiology interact. AgNPs support gut health by specifically targeting harmful gut bacteria while maintaining beneficial microbiota [46]. Although research is needed to determine the long-term effects on the microbiome, this modulation may offer promise for infections linked to dysbiosis, such as *C. difficile* colitis [47]. Through a feedback loop in which microbes create NPs to target pathogens, microbes such as *E. coli* and *S. aureus* model NP-pathogen interactions and promote microbiological innovation.

Challenges and Limitations

High concentrations of NP therapies can be cytotoxic, which makes biocompatible coatings necessary [48]. Scalability is hampered by microbial synthesis's inability to produce NPs with consistent size and yield. Effectiveness is threatened by bacterial resistance to NPs through efflux pumps, and regulatory barriers necessitate thorough safety assessments. To reduce the effects on the environment, eco-friendly synthesis is required.

Future Directions

Hybrid NPs that combine antimicrobial mechanisms, synthetic biology for accurate synthesis, CRISPR integration for pathogen targeting, and AI-driven NP design for optimal formulations are examples of future NP advancements [49]. Nano diagnostics for real-time pathogen detection and customized NP therapies based on patient microbiomes hold promise for improving the management of infectious diseases.

CONCLUSION

Through effective antimicrobial mechanisms, sustainable microbial synthesis, and novel therapeutics, nanoparticles revolutionize the control of infectious diseases. NPs overcome MDR, improve treatment efficacy, and integrate with microbiology for diagnostics and microbiome modulation by treating tuberculosis, pneumonia, UTIs, skin infections, H. pylori, and C. difficile infections. Notwithstanding obstacles, developments in AI, CRISPR, and hybrid NPs hold the potential to completely transform global health outcomes.

Acknowledgments

We thank all authors for their valuable feedback and insights during the preparation of this review article.

REFERENCES

1. Ventola, C. L. (2015). The antibiotic resistance crisis: Part 1: Causes and threats. *Pharmacy and Therapeutics, 40*(4), 277–283.
2. World Health Organization. (2020). *Antimicrobial resistance: Global report on surveillance*. WHO Press.
3. Wang, L., Hu, C., & Shao, L. (2017). The antimicrobial activity of nanoparticles: Present situation and prospects for the future. *International Journal of Nanomedicine, 12*, 1227–1249. https://doi.org/10.2147/ijn.s121956
4. Hulkoti, N. I., & Taranath, T. C. (2014). Biosynthesis of nanoparticles using microbes—A review. *Colloids and Surfaces B: Biointerfaces, 121*, 474–483. https://doi.org/10.1016/j.colsurfb.2014.05.027
5. Beyth, N., Houri-Haddad, Y., Domb, A., Khan, W., & Hazan, R. (2015). Alternative antimicrobial approach: Nano-antimicrobial materials. *Evidence-Based Complementary and Alternative Medicine, 2015*, 1–16. https://doi.org/10.1155/2015/246012
6. Sondi, I., & Salopek-Sondi, B. (2004). Silver nanoparticles as antimicrobial agent: A case study on *E. coli* as a model for Gram-negative bacteria. *Journal of Colloid and Interface Science, 275*(1), 177–182. https://doi.org/10.1016/j.jcis.2004.02.012
7. Dizaj, S. M., Lotfipour, F., Barzegar-Jalali, M., Zarrintan, M. H., & Adibkia, K. (2014). Antimicrobial activity of the metals and metal oxide nanoparticles. *Materials Science and Engineering: C, 44*, 278–284. https://doi.org/10.1517/17425247.2015.1049530

8. Ahmad, T., Wani, I. A., Lone, I. H., Ganguly, A., Manik, S., & Ahmad, A. (2013). Antifungal activity of gold nanoparticles prepared by solvothermal method. *Materials Research Bulletin, 48*(1), 12–20. https://doi.org/10.1016/j.materresbull.2012.09.069
9. Li, Q., Mahendra, S., Lyon, D. Y., Brunet, L., Liga, M. V., Li, D., & Alvarez, P. J. (2008). Antimicrobial nanomaterials for water disinfection and microbial control: Potential applications and implications. *Water Research, 42*(18), 4591–4602. https://doi.org/10.1016/j.watres.2008.08.015
10. Raghupathi, K. R., Koodali, R. T., & Manna, A. C. (2011). Size-dependent bacterial growth inhibition and mechanism of antibacterial activity of zinc oxide nanoparticles. *Langmuir, 27*(7), 4020–4028. https://doi.org/10.1021/la104825u
11. Martinez-Gutierrez, F., Olive, P. L., Banuelos, A., Orrantia, E., Nino, N., Sanchez, E. M., ... & Ruiz, F. (2010). Synthesis, characterization, and evaluation of antimicrobial and cytotoxic effect of silver and titanium nanoparticles. *Nanomedicine: Nanotechnology, Biology and Medicine, 6*(5), 681–688. https://doi.org/10.1016/j.nano.2010.02.001
12. Lemire, J. A., Harrison, J. J., & Turner, R. J. (2013). Antimicrobial activity of metals: Mechanisms, molecular targets and applications. *Nature Reviews Microbiology, 11*(6), 371–384. https://doi.org/10.1038/nrmicro3028
13. Galdiero, S., Falanga, A., Vitiello, M., Cantisani, M., Marra, V., & Galdiero, M. (2011). Silver nanoparticles as potential antiviral agents. *Molecules, 16*(10), 8894–8918. https://doi.org/10.3390/molecules16108894
14. Klaus, T., Joerger, R., Olsson, E., & Granqvist, C. G. (1999). Silver-based crystalline nanoparticles, microbially fabricated. *Proceedings of the National Academy of Sciences, 96*(24), 13611–13614. https://doi.org/10.1073/pnas.96.24.13611
15. De Windt, W., Aelterman, P., & Verstraete, W. (2005). Bioreductive deposition of palladium (0) nanoparticles on *Shewanella oneidensis* with catalytic activity towards reductive dechlorination. *Environmental Microbiology, 7*(3), 314–325.
16. Mukherjee, P., Ahmad, A., Mandal, D., Senapati, S., Sainkar, S. R., Khan, M. I., ... & Sastry, M. (2001). Fungus-mediated synthesis of silver nanoparticles and their immobilization in the mycelial matrix: A novel biological approach to nanoparticle synthesis. *Nano Letters, 1*(10), 515–519. https://doi.org/10.1021/nl0155274
17. Gholami-Shabani, M., Shams-Ghahfarokhi, M., & Razzaghi-Abyaneh, M. (2016). Biosynthesis of nanoparticles by fungi: Applications in biotechnology. *Mycology, 7*(2), 81–89. https://doi.org/10.1007/978-981-10-8666-3_4
18. Annamalai, J., & Nallamuthu, T. (2016). Green synthesis of silver nanoparticles: Characterization and determination of antibacterial activity. *Applied Nanoscience, 6*(2), 259–265. https://doi.org/10.1007/s13204-015-0426-6
19. Ahmed, S., Ahmad, M., Swami, B. L., & Ikram, S. (2016). A review on plants extract mediated synthesis of silver nanoparticles for antimicrobial applications: A green expertise. *Journal of Advanced Research, 7*(1), 17–28. https://doi.org/10.1016/j.jare.2015.02.007
20. Singh, P., Kim, Y. J., Zhang, D., & Yang, D. C. (2016). Biological synthesis of nanoparticles from plants and microorganisms. *Trends in Biotechnology, 34*(7), 588–599. https://doi.org/10.1016/j.tibtech.2016.02.006
21. Liu, J., & Jiang, X. (2015). Advances in nanoparticle-based drug delivery for bacterial infections. *Current Opinion in Microbiology, 27*, 86–93.
22. Pandey, R., & Khuller, G. K. (2005). Antitubercular inhaled therapy: Opportunities, progress and challenges. *Journal of Antimicrobial Chemotherapy, 55*(4), 430–435. https://doi.org/10.1093/jac/dki027
23. Vallet-Regí, M., Balas, F., & Arcos, D. (2008). Mesoporous materials for drug delivery. *Angewandte Chemie International Edition, 47*(5), 7548–7558. https://doi.org/10.1002/anie.200604488
24. Li, P., Li, J., Wu, C., Wu, Q., & Li, J. (2005). Synergistic antibacterial effects of β-lactam antibiotic combined with silver nanoparticles. *Nanotechnology, 16*(9), 1912–1917. https://doi.org/10.1088/0957-4484/16/9/082
25. Mu, H., Guo, F., Niu, H., Liu, Y., Zhang, S., & Wang, Y. (2014). Chitosan nanoparticles for enhanced drug delivery to biofilms. *Colloids and Surfaces B: Biointerfaces, 117*, 203–209.
26. Hetrick, E. M., Shin, J. H., Paul, H. S., & Schoenfisch, M. H. (2009). Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles. *Biomaterials, 30*(14), 2782–2789. https://doi.org/10.1016/j.biomaterials.2009.01.052
27. Jeremiah, S. S., Miyakawa, K., Morita, T., Yamaoka, Y., & Ryo, A. (2020). Potent antiviral effect of silver nanoparticles on SARS-CoV-2. *Biochemical and Biophysical Research Communications, 533*(1), 195–200. https://doi.org/10.1016/j.bbrc.2020.09.018
28. Kim, J., Yeom, M., Lee, J., & Shin, H. (2011). Amphotericin B-loaded polymeric nanoparticles for antifungal therapy. *Journal of Controlled Release, 152*(Suppl 1), e133–e134.
29. Innocenzi, P., & Stagi, L. (2020). Graphene-based materials for antimicrobial applications. *Applied Sciences, 10*(17), 5977. https://doi.org/10.1039/d0sc02658a
30. Augustine, R., Kalarikkal, N., & Thomas, S. (2014). Role of wound dressing in the management of chronic wounds: A review. *Journal of Alloys and Compounds, 614*, 343–351.
31. Sawai, J. (2003). Quantitative evaluation of antibacterial activities of metallic oxide powders (ZnO, MgO and CaO) by conductimetric assay. *Journal of Microbiological Methods, 54*(2), 177–182. https://doi.org/10.1016/s0167-7012(03)00037-x
32. World Health Organization. (2021). *Global tuberculosis report 2021*. WHO Press.
33. Torres, A., Peetermans, W. E., Viegi, G., & Blasi, F. (2013). Risk factors for community-acquired pneumonia in adults in Europe: A literature review. *Thorax, 68*(11), 1057–1065. https://doi.org/10.1136/thoraxjnl-2013-204282
34. Dube, A., Reynolds, J. L., Law, W. C., Maponga, C. C., Prasad, P. N., & Morse, G. D. (2014). Multimodal nanoparticles that provide immunoprotection and intracellular drug delivery for infectious diseases. *Nanomedicine: Nanotechnology, Biology and Medicine, 10*(4), 831–838.
35. Singh, R., Nawale, L., Arkile, M., Wadhwani, P., Shedbalkar, U., Chopade, B., ... & Vidyasagar, P. (2016). Silver nanoparticles: A novel antimycobacterial agent against *Mycobacterium tuberculosis*. *Nanotechnology, 27*(8), 085107. https://doi.org/10.1016/j.ijantimicag.2015.03.014
36. Chuan, J., Li, Y., Yang, L., Sun, X., Zhang, Q., Gong, T., & Zhang, Z. (2013). Enhanced rifampicin delivery to alveolar macrophages by liposome encapsulation. *International Journal of Pharmaceutics, 448*(1), 135–141.
37. Jiang, J., Pi, J., & Cai, J. (2018). Zinc oxide nanoparticles for the treatment of bacterial infections. *Frontiers in Microbiology, 9*, 2709. https://doi.org/10.1155/2018/1062562
38. Brown, A. N., Smith, K., Samuels, T. A., Lu, J., Obare, S. O., & Scott, M. E. (2012). Nanoparticles functionalized with ampicillin destroy multiple-antibiotic-resistant isolates of *Pseudomonas aeruginosa* and *Enterobacter aerogenes* and

methicillin-resistant *Staphylococcus aureus*. *Applied and Environmental Microbiology, 78*(8), 2768–2774.
39. Ahmadi, A., Ahmadi, P., Ehsani, A., & Mahmoudi, M. (2020). Copper oxide nanoparticles as an effective anti-biofilm agent against *Klebsiella pneumoniae*. *Journal of Medical Microbiology, 69*(6), 831–837.
40. Shariati, A., Hosseini, S. M., Chegini, Z., Seifalian, A., & Arabestani, M. R. (2020). Chitosan-based nanoparticles for the treatment of bacterial infections. *International Journal of Biological Macromolecules, 165*(Pt A), 1392–1402. https://doi.org/10.1016/j.biopha.2022.114184
41. Qais, F. A., Shafiq, A., Khan, H. M., Husain, F. M., Khan, R. A., Alenazi, B., ... & Ahmad, I. (2019). Antibacterial effect of silver nanoparticles synthesized using *Murraya koenigii* against *Proteus mirabilis*. *Nanomaterials, 9*(3), 441. https://doi.org/10.1155/2019/4649506
42. Wang, Y., Zhang, L., Wang, X., & Zhang, Y. (2021). Selenium nanoparticles as a new strategy to combat *Escherichia coli*-induced urinary tract infections. *Journal of Nanobiotechnology, 19*(1), 112.
43. Rai, M., Yadav, A., & Gade, A. (2009). Silver nanoparticles as a new generation of antimicrobials. *Biotechnology Advances, 27*(1), 76–83. https://doi.org/10.1016/j.biotechadv.2008.09.002
44. Gu, H., Ho, P. L., Tong, E., Wang, L., & Xu, B. (2003). Presenting vancomycin on nanoparticles to enhance antimicrobial activities. *Nano Letters, 3*(9), 1261–1263. https://doi.org/10.1021/nl034396z
45. Jesline, A., John, N. P., Narayanan, P. M., Vani, C., & Murugan, S. (2015). Antimicrobial activity of zinc and titanium dioxide nanoparticles against biofilm-producing methicillin-resistant *Staphylococcus aureus*. *Applied Nanoscience, 5*(2), 157–162. https://doi.org/10.1007/s13204-014-0301-x
46. Yausheva, E., Sizova, E., Lebedev, S., Skalny, A., & Miroshnikov, S. (2020). Effects of silver nanoparticles on the gut microbiota of rats. *Nanomaterials, 10*(7), 1351. https://doi.org/10.1007/s11356-016-6474-y
47. Pietroiusti, A., Magrini, A., & Campagnolo, L. (2016). New frontiers in nanotoxicology: Gut microbiota/microbiome-mediated effects of engineered nanomaterials. *Toxicology and Applied Pharmacology, 299*, 90–95. https://doi.org/10.1016/j.taap.2015.12.017
48. Lewinski, N., Colvin, V., & Drezek, R. (2008). Cytotoxicity of nanoparticles. *Small, 4*(1), 26–49. https://doi.org/10.1002/smll.200700595
49. Angsantikul, P., Thamphiwatana, S., Zhang, Q., Spiekermann, K., Zhuang, J., Fang, R. H., ... & Zhang, L. (2018). Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery against *Helicobacter pylori* infection. *Advanced Therapeutics, 1*(2), 1800016. https://doi.org/10.1002/adtp.201800016
50. Lee, N.-Y., Ko, W.-C., & Hsueh, P.-R. (2019). Nanoparticles in the treatment of infections caused by multidrug-resistant organisms. *Frontiers in Pharmacology, 10*, 1153. https://doi.org/10.3389/fphar.2019.01153